Chiasma Inc (NASDAQ:CHMA) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.25 and last traded at $4.25, with a volume of 499 shares. The stock had previously closed at $4.08.

Separately, ValuEngine raised shares of Chiasma from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

Chiasma (NASDAQ:CHMA) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.36).

In related news, Director Scott Minick bought 25,000 shares of the company’s stock in a transaction dated Thursday, September 20th. The stock was bought at an average price of $3.08 per share, with a total value of $77,000.00. Following the transaction, the director now owns 62,531 shares of the company’s stock, valued at $192,595.48. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 6.20% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Chiasma stock. Point72 Asset Management L.P. raised its stake in Chiasma Inc (NASDAQ:CHMA) by 10.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 896,600 shares of the biotechnology company’s stock after purchasing an additional 81,205 shares during the period. Point72 Asset Management L.P. owned 3.68% of Chiasma worth $1,345,000 as of its most recent SEC filing. Institutional investors own 60.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Chiasma (CHMA) Reaches New 52-Week High at $4.25” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at

Chiasma Company Profile (NASDAQ:CHMA)

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Featured Story: What are defining characteristics of a correction?

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.